Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 6

1.
Figure 6

Figure 6. From: Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Histogram of risperidone clearance estimates (CL)

Yan Feng, et al. Br J Clin Pharmacol. 2008 November;66(5):629-639.
2.
Figure 5

Figure 5. From: Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

9-OH risperidone clearance (CLM) vs. age. Line represents the smooth line

Yan Feng, et al. Br J Clin Pharmacol. 2008 November;66(5):629-639.
3.
Figure 3

Figure 3. From: Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Base population pharmacokinetic model structure for risperidone and 9-OH risperidone, KF is the fraction of risperidone to 9-OH risperidone

Yan Feng, et al. Br J Clin Pharmacol. 2008 November;66(5):629-639.
4.
Figure 1

Figure 1. From: Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Frequency histogram showing the age (a) and weight (b) distribution for all subjects in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-SZ and CATIE-AD studies

Yan Feng, et al. Br J Clin Pharmacol. 2008 November;66(5):629-639.
5.
Figure 2

Figure 2. From: Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Frequency histogram showing the sampling distribution for risperidone sampling measurements in Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-SZ (a) and CATIE-AD (b) studies. The abscissa is broken into 1-h bins. The ordinate is the proportion of samples taken in each interval

Yan Feng, et al. Br J Clin Pharmacol. 2008 November;66(5):629-639.
6.
Figure 4

Figure 4. From: Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Diagnostic plots of final pharmacokinetic model. (a,e) Plot of observed concentrations vs. population predicted risperidone (a) and 9-OH risperidone (e) concentrations. Dots represent individual data points; solid line represents the unity line and dashed line represents the smooth line. (b,f) Plot of observed concentrations vs. individual population predicted risperidone (b) and 9-OH risperidone (f) concentrations. Dots represent individual data points; solid line represents the unity line and dashed line represents the smooth line. (c,g) Plot of weighted residual error (WRES) vs. population predicted risperidone (c) and 9-OH risperidone (g) concentrations. Dashed line represents the smooth line. (d,h) Plot of WRES vs. time after most recent dose for risperidone (d) and 9-OH risperidone (h). Dashed line represents the smooth line

Yan Feng, et al. Br J Clin Pharmacol. 2008 November;66(5):629-639.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is temporarily unavailable.

Write to the Help Desk